Summary Transforming growth factor β (TGF-β) exerts a growth inhibitory effect on many cell types through binding to two types of receptors, the type I and II receptors. Resistance to TGF-β due to lack of type II receptor (RII) has been described in some cancer types including small cell lung cancer (SCLC). The purpose of this study was to examine the cause of absent RII expression in SCLC cell lines. Northern blot analysis showed that RII RNA expression was very weak in 16 of 21 cell lines. To investigate if the absence of RII transcript was due to mutations, we screened the poly-A tract for mutations, but no mutations were detected. Additional screening for mutations of the RII gene revealed a GG to TT base substitution in one cell line, which did not express RII. This mutation generates a stop codon resulting in predicted synthesis of a truncated RII of 219 amino acids. The nature of the mutation, which has not previously been observed in RII, has been linked to exposure to benzo[a]-pyrene, a component of cigarette smoke. Since RII has been mapped to chromosome 3p22 and nearby loci are often hypermethylated in SCLC, it was examined whether the lack of RII expression was due to hypermethylation. Southern blot analysis of the RII promoter did not show altered methylation patterns. The restriction endonuclease pattern of the RII gene was altered in two SCLC cell lines when digested with Sma1. However, treatment with 5-aza-2′-deoxycytidine did not induce expression of RII mRNA. Our results indicate that in SCLC lack of RII mRNA is not commonly due to mutations and inactivation of RII transcription was not due to hypermethylation of the RII promoter or gene. Thus, these data show that in most cases of the SCLC cell lines, the RII gene and promoter is intact in spite of absent RII expression. However, the nature of the mutation found could suggest that it was caused by cigarette smoking.
Transforming growth factor β (TGF-β) is an important regulator of cell proliferation, differentiation and formation of extracellular matrix (Roberts and Sporn, 1990; Moses, 1992; Kingsley, 1994) . The effects of TGF-β are mediated through binding to two ubiquitously expressed receptors, TGF-β receptor type I (RI), and type II (RII). RI and RII contain cytoplasmic serine/threonine kinase domains and act in concert by heterodimerization (Wrana et al, 1994) . One of the most pronounced effects of TGF-β in vitro is growth inhibition of ectodermally derived cells (for review see N¿rgaard et al, 1995) . Some carcinomas are resistant to the growth inhibitory effect of TGF-β, which in several cases has been ascribed to lack of RII (Geiser et al, 1992; Inagaki et al, 1993; N¿rgaard et al, 1994; Park et al, 1994) . Recently, it was shown that TGF-β 1 acts as a growth inhibitor of carcinomas in vivo, at least during early tumour growth (Cui et al, 1994 (Cui et al, , 1996 Pierce et al, 1995) . In colon and gastric cancer, showing the replication error phenotype, a high incidence of mutations in the poly-adenosine (poly-A) tract of the RII gene was found leading to loss of RII .
Lung cancer is divided into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Both types are characterized by gross chromosomal rearrangements of which loss of heterozygosity at the short arm of chromosome 3 is very frequent (Mitsudomi et al, 1996; Todd et al, 1997) . Interestingly, the RII gene has been reported to map to chromosome 3p22 (Mathew et al, 1994) and nearby loci have been found to be hypermethylated in SCLC (Makos et al, 1995) . Of 35 SCLC and NSCLC tumour specimens with chromosome 3p loss examined for RII mutations, only one SCLC tumour harboured a mutation in the poly-A tract. The SCLC tumour showed a replication error phenotype (Tani et al, 1997) . Mutations in the poly-A tract of the RII gene therefore seem to be infrequent in lung cancer.
We have previously shown that a number of SCLC cell lines did not express RII protein (Damstrup et al, 1993) , rendering them resistant to the growth inhibitory effect of TGFβ 1 (N¿rgaard et al, 1994, 1996) . In this report we characterized the expression of RNA for RII in a panel of 21 SCLC cell lines and found that 16 cell lines showed very weak expression. In one cell line we identified a mutation generating a stop codon which predicts synthesis of a truncated RII protein lacking the serine/threonine kinase domain. This particular type of mutation has been linked to exposure to benzo[a]-pyrene, a component of cigarette smoke. We investigated whether lack of RII transcript was due to hypermethylation of the promoter, but found that this was not the case. In two cell lines Southern blot analysis revealed an altered restriction pattern of the RII gene, but treatment with 5-aza-2′-deoxycytidine (5-azaCdR) did not increase RII expression. We conclude that in the majority of SCLC cell lines, the RII gene and promoter is intact. However, interestingly, the nature of the found mutation suggests that it could be attributed to cigarette smoking. 
MATERIALS AND METHODS

Cell lines
SCLC cell lines were cultured in 150 cm 2 culture flasks at 37°C under standard conditions in medium containing 10% heat inactivated fetal calf serum (FCS; Gibco BRL) without antibiotics. All cell lines were routinely tested for mycoplasma contamination and were found negative. Eight cell lines (DMS) were established at Dartmouth Medical School (Hanover, NH, USA) and cultured in Waymouth medium (GIBCO). Seven cell lines (GLC) were established at Groningen Lung Cancer Centre (Groningen, The Netherlands), two cell lines (NCI) were established at the National Cancer Institute (Bethesda, MD, USA), and two cell lines (24H and 86M1) were established in Marburg, Germany. They were cultured in RPMI-1640 (GIBCO). Finally, two cell lines (CPH) were established in our own laboratory (Copenhagen, Denmark) and cultured in EagleÕs minimum essential medium (EMEM; GIBCO). The origin and establishment of the cell lines have previously been described in (Pettengill et al, 1980; Carney et al, 1985; De Leij et al, 1985; Engelholm et al, 1986; Berendsen et al, 1988; Vincent et al, 1997) . Primary human foreskin fibroblasts (HFF; a gift from O Pettengill, Dartmouth Medical School) were grown in Hanks basal medium Eagle (BME; GIBCO). Cells for investigations were harvested during exponential growth, washed in phosphatebuffered saline (PBS) (Dulbeccos; GIBCO), centrifuged at 300 g, immediately frozen in liquid nitrogen, and stored at Ð 80°C.
RNA extraction, electrophoresis and blotting
Total RNA was isolated by use of TRIzol 8 LS REagent (GibcoBRL, Life Technologies) as recommended. Subsequent Northern blot analysis was performed as previously described (N¿rgaard et al, 1995) . The Northern blots were analysed by phosphor imager (STORM, Molecular Dynamics). The blots were hybridized with a 32 P-labelled RII probe, a 930 bp PstIÐSacI fragment of the cloned 4.5 kb H2-3FF human cDNA, kindly provided by HY Lin (Lin et al, 1992) . To ensure equal loading of RNA present on the membrane, the blots were hybridized with a 32 Plabelled glyceraldehyde 3-phosphate dehydrogenase (GAPDH) probe, a 1.1 kb cDNA fragment purchased from Clontech hybridizing to a single ~ 1.4 kb mRNA.
SSCP analysis
From each cell line, cDNA was obtained by reverse transcriptase polymerase chain reaction (RT-PCR) according to recommendations (1st Strand cDNA Synthesis Kit for RT-PCR, Boehringer Mannheim). A 269 basepair (bp) GAPDH fragment was generated by PCR to test the cDNA reaction by use of the primers described in Liabakk et al (1996) . A 1678 bp RII fragment (from bp 35 to 1713) was generated by PCR with the primers: 5′-GCACATCGTCCT-GTGGACGCGTA and 5′-CCTGCCCCATAAAGAGCTATTTGG.
For subsequent generation of 250 to 363 bp fragments the following primers were used:
From bp Ð 304 to 59: 5′-GCGCTGAGTTGAAGTTGAGTGAGT 5′-ATACGCGTCCACAGGAACGATGTGC.
In this case single-stranded confirmational polymorphism (SSCP) was performed on PCR fragments generated utilizing genomic DNA as template. PCR comprised 30 cycles at 94°C for 30 s, 55Ð60°C for 1 min, and 72°C for 1 min to generate the 250Ð327 bp fragments and 2 min for the 1678 bp fragment. The PCR reactions were carried out with Thermoprime Plus DNA polymerase (Applied Biochemistry) in standard solutions. SSCP analysis was performed using non-denaturating 5% acrylamide gels with 0%, 5%, or 10% glycerol. The running conditions were 400 V for 1.5Ð2.5 h at 5°C or 10°C using a vertical electrophoresis apparatus (Hoefer, serie 600). The gels were stained with SYBR green (Medinova) and analysed by a fluorescence imager (STORM, Molecular Dynamics).
DNA sequencing
DNA fragments, which showed aberrant migration in the SSCP analysis were de novo amplified by PCR. PCR products were purified using MicroSpin S-400 HR Columns (Pharmacia). The fragments were sequenced by Thermo Sequenase 33 P-labelled terminator cycle sequencing kit (Amersham, Life Science). The samples were run on a standard acrylamide/urea gel and autoradiography was subsequently performed.
Analysis of the poly-A tract
A fragment from bp 329 to 401 from each cell line was generated by PCR as previously described using genomic DNA as template. The samples were electrophoresed on a 6% acrylamide gel followed by autoradiography.
DNA extraction, electrophoresis and blotting
DNA was extracted with phenol and chloroform by standard methods (Sambrook et al, 1989) , and digested with the restriction endonucleases (RE): BsmI with one of the following methylation sensitive RE: SmaI, Bst4I, HinPI, AatII, each of which has one recognition site in the 3′-end of the promoter and the 5′-end of the RII untranslated region. Digestion was performed as recommended by the supplier (New England Biolabs) using 10 U of each methylation sensitive RE/mg DNA and incubation for 18 h. DNA (10 mg/lane) was electrophoresed on 0.8% agarose gels and transferred to charged nylon membranes (GeneScreenPlus, NEN/DuPont). Prehybridization, hybridization and washing were performed as recommended by the supplier. Washing stringency was 2 × SSC, 1% sodium dodecyl sulphate twice for 30 min at 60°C. Southern blots were probed with both 32 P-labelled fulllength RII cDNA probe and a probe for the promoter. The latter probe was generated by PCR using the primers 5′-ATCTG-GTTGCCCTAGCAAGA and 5′-ATACGCGTCCACAGGAAC-GATGTGC, which generated a fragment of 1306 bp covering the region from nucleotide Ð1247 to 59. The template was genomic DNA from HFF. Membranes were exposed to X-ray film (Amersham) at Ð 80°C with an intensifying screen for 7 days.
Treatment with 5-azaCdR
Two cell lines showing altered RE-pattern with digestion with SmaI, DMS 79, DMS 114 (both RII-negative), GLC 2 (RII-negative), and CPH 54A (RII-positive) were treated with 0.5, 0.75 and 2.0 mM 5-azaCdR (Sigma). The cells were treated for two doubling times (respectively 83, 31, 26 and 43 h for each cell line). The cells were harvested as described above at start, at one doubling time and at two doubling times. To demonstrate a possible induction of RII, total RNA was isolated by use of TRIzol 8 LS REagent (GibcoBRL, Life Technologies) as recommended. cDNA was obtained as described in SSCP analysis, and expression of the receptor was detected by use of the above mentioned primers generating a 508 bp 5′-end transcript.
RESULTS
RII mRNA expression
Expression of RII mRNA was examined in 21 SCLC cell lines by Northern blot analysis. The cell lines CPH 54A, CPH 54B, GLC 16, GLC 19 and DMS 273 expressed significant amounts of ã 5.5 kb mRNA for RII, whereas the rest of the cell lines showed very weak expression (Figure 1 ). This correlated with previous findings where RII protein expression was detected by chemical cross-linking (Damstrup et al, 1993) .
Screening for mutations of RII
It has previously been reported that mutations in the poly-A tract of the RII gene have been associated with reduced, or lack of, RII transcript and hence we analysed the cell lines for mutations in the poly-A tract (nucleotides 383Ð392) but found no alterations (data not shown). Next we screened the RII gene for mutation by SSCP analysis followed by sequencing. In two cell lines, GLC 26 and DMS 456, the fragment representing bp 491Ð780 migrated aberrantly (Figure 2) . Subsequent sequencing revealed a mutation in DMS 456. The mutation was a GG to TT base substitution at nucleotides 658Ð659 ( Figure 3A ). This substitution converts the wild-type glutamic acid to a stop codon at amino acid 220 in exon 4 ( Figure 3B ). The presence of the mutation was confirmed at the level of genomic DNA. The transcript mutated in the serine/threonine kinase domain encodes a predicted inactive RII receptor if translated. The aberrant migrating band in GLC 26 was of lower molecular weight than in case of DMS 456 (Figure 2 ). The band was reproduced at several occasions, but it is presumably of no significance, since sequencing did not reveal any mutation in GLC 26.
Analysis for altered methylation pattern
To investigate the reason for lack of RII transcript in 16 of the 21 SCLC cell lines, we examined all the SCLC cell lines for altered methylation pattern in the 3′-end of the promoter and the 5′-end of the untranslated region of the RII gene. This region fulfills the criteria for a C/G island, having a C/G content over 70%. Digestion with four different methylation sensitive REs, each having recognition sites in the RII promoter, followed by Southern blotting and hybridization with RII promoter probe, did not reveal alterations of the promoter and with that no signs of altered methylation of the RII promoter.
However, when the same Southern blots were hybridized with the probe for the RII gene, it was found that in the case of the SmaI/BsmI digestion the RE pattern was altered in two cell lines, DMS 79 and DMS 114 (Figure 4) . Digestion with the three other combinations of REs showed an identical pattern in all the SCLC cell lines indicating no gross structural changes of the RII gene (data not shown). To examine if the altered RE pattern in DMS 79 and DMS 114 could be due to hypermethylation of the RII gene, which could inactivate RII expression, we treated the cell lines with 5-azaCdR. The response to 5-azaCdR treatment was evaluated by detecting increased induction of RII RNA transcript. Treatment with 5-azaCdR for two doubling times did not increase transcription of the RII gene in either the two cell lines, or in another RII-negative cell line (GLC 2), and transcription did not increase in a RII-positive cell line (CPH 54A). We therefore concluded that the silencing of the RII gene was not due to hypermethylation of the RII gene in DMS 79 and DMS 114. The observation that the two cell lines exhibited an altered RE pattern with
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British Journal of Cancer (1999) 54A  54B  2  3  14  16  19  26  28  53  79  92  114  153  273  406  456  H69  417N (B) Schematic representations of the sequence of wild-type RII mRNA and RII mRNA from DMS 456. The seven exons are indicated by numbers and the predicted translated protein is illustrated with the signal sequence, the cysteine-rich sequence, the transmembrane (TM) and the serine/threonine kinase domain digestion with SmaI could indicate that they contain an altered sequence in an intron at a particular recognition site for SmaI. Although the genomic structure of the RII gene has recently been described (Lu et al, 1996) , the sequence of the introns between the seven exons has not been described. Accordingly, the precise restriction pattern cannot be deduced.
DISCUSSION
We previously found that a number of SCLC cell lines did not express RII protein (Damstrup et al, 1993) and that sensitivity to the growth inhibitory effect of TGFβ 1 correlated to expression of RII in five cell lines, while four cell lines not expressing RII were resistant to TGFβ 1 (N¿rgaard et al, 1994, 1996) . We examined 21 SCLC cell lines for expression of RII RNA. Sixteen of the 21 cell lines showed weak expression of the RII RNA (Figure 1 ), which correlated with the previously published protein expression (Damstrup et al, 1993) .
Mutations in the RII gene have been detected in human cancers of the colon (Lu et al, 1995; Markowitz et al, Myeroff et al, 1995) , stomach (Park et al, 1994) , endometrium , and head and neck (Garrigue-Antar et al, 1995) . These observations are consistent with the proposal that RII is a tumour suppressor gene and that inactivation of RII could be involved in human carcinogenesis (Sun et al, 1994; Wang et al, 1995) . RII mutations have been detected frequently in the poly-A tract in tumours with microsatellite instability (Lu et al, 1995; Markowitz et al, 1995; Myeroff et al, 1995) , suggesting that RII mutations occur preferentially in microsatellite regions and in tumours with genomic instability. We did not find mutations in the poly-A tract, which is in agreement with another study where only one of 15 SCLC tumour specimens harboured a mutation at this site (Tani et al, 1997) . Mutations in the serine/threonine kinase domain of the RII gene have also been found (Lu et al, 1995; Garrigue-Antar et al, 1997) and in this paper we describe a mutation in exon 4, which results in a truncated receptor lacking the kinase domain. However, this mutation per se cannot account for the observed lack of RII RNA. Recently, it has been described that 11 SCLC cell lines expressed low levels of RII, and one cell line expressed a truncated RII transcript (de Jonge et al, 1997) . The exact position of the truncation was not determined, but it was located within exon 4. However, the RII gene was screened for mutations in only four of the cell lines. In contrast, we did not find a truncated RNA transcript, but rather a mutation that would lead to a truncated receptor if translated.
From the present data it is not possible to deduce the succession of pathogenetic events; i.e. whether the mutation was preceded by silencing of the RII gene or vice versa. However, the type of mutation implies that this may not be an in vitro phenomenon, since occurrence of the G to T transversion in lung cancer mutational hotspots was previously shown to correlate with the formation of carcinogenic benzo[a]-pyrene metabolites found in cigarette smoke (Denissenko et al, 1996) . Benzo[a]-pyrene induces specific mutations of the p53 gene and, interestingly, a similar G to T transversion was also found in the p53 gene of this particular SCLC cell line (Abrahamsen et al, unpublished results), supporting the assumption that the mutation of RII could have been a result of cigarette smoking. To our knowledge this kind of mutation of the RII gene has not been described previously.
In cancers, methylation of CpG islands in the promoter regions of various genes is one established mechanism for regulating transcriptional activity (Ferguson et al, 1995; Gonzalez-Zulaeta et al, 1995; Graff et al, 1995) . The RII gene has been mapped to chromosome 3p22 (Mathew et al, 1994) and tumour suppressor genes associated with lung carcinogenesis have been suggested to be present on chromosome 3p since loss of heterozygosity at this chromosome occurs frequently in SCLC . Furthermore, it has been shown that nearby loci to the location of the RII gene are hypermethylated in SCLC (Makos et al, 1995) . However, we did not find any altered restriction pattern of the RII promoter. This is in agreement with a previous report where no hypermethylation was found of the RII promoter (de Jonge et al, 1997) . We found two cell lines with an altered restriction pattern of the RII gene when digested with SmaI, but transcription of RII was not increased with 5-azaCdR treatment. Thus, the RII gene of these two cell lines must harbour an alteration at a SmaI site of unknown position, possibly in an intron, since no mutations in SmaI sites in the promoter or in the gene at exon 4 were found. The
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British Journal of Cancer (1999) Figure 4 Southern blot performed with genomic DNA from 21 SCLC cell lines digested with BsmI and the methylation sensitive SmaI. The RII-negative cell lines DMS 79 and DMS 114 showed an altered digestion pattern significance of the alteration in these two cell lines in relation to lack of RII expression remains uncertain. In gastric cancer cell lines genomic alterations of the RII gene have been described, both deletions and amplifications (Park et al, 1994) . However, our observation is not quite similar, since only a specific combination of REs revealed a genomic alteration of the RII gene.
Our results indicate that alterations of the RII gene per se are not a major genetic basis of the malignant phenotype of SCLC, in contrast to gastrointestinal cancers . We did not find a high frequency of RII mutations in SCLC and we did not find an altered methylation pattern of the gene or promoter, which could account for the observed lack of RII expression. The cause of the silencing of the RII gene transcript is so far unknown, but may be due to alterations or defects in the transcriptional apparatus.
